Manuel R. Teixeira

List of Publications by Year
in descending order

319 papers	16,465 citations	18482 62 h-index	26613 107 g-index
340 all docs	340 docs citations	340 times ranked	22829 citing authors

#	Article	IF	Citations
1	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	21.4	652
2	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics, 2013, 45, 385-391.	21.4	492
3	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nature Genetics, 2014, 46, 1103-1109.	21.4	408
4	The MLL recombinome of acute leukemias in 2013. Leukemia, 2013, 27, 2165-2176.	7.2	393
5	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	7.4	390
6	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
7	SMARCB1/INI1 Tumor Suppressor Gene Is Frequently Inactivated in Epithelioid Sarcomas. Cancer Research, 2005, 65, 4012-4019.	0.9	316
8	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
9	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	21.4	265
10	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75.	21.4	264
11	Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. Nature, 2014, 508, 98-102.	27.8	261
12	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, .	6.3	242
13	A Quantitative Promoter Methylation Profile of Prostate Cancer. Clinical Cancer Research, 2004, 10, 8472-8478.	7.0	234
14	TMPRSS2-ERG Gene Fusion Causing ERG Overexpression Precedes Chromosome Copy Number Changes in Prostate Carcinomas, Paired HGPIN Lesions. Neoplasia, 2006, 8, 826-832.	5.3	225
15	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
16	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
17	Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology, 2014, 66, 489-499.	1.9	195
18	PALB2,CHEK2andATMrare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	3.2	174

#	Article	IF	Citations
19	Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. Blood, 2016, 127, 3026-3034.	1.4	168
20	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	9.4	157
21	Three Epigenetic Biomarkers, GDF15, TMEFF2, and VIM, Accurately Predict Bladder Cancer from DNA-Based Analyses of Urine Samples. Clinical Cancer Research, 2010, 16, 5842-5851.	7.0	155
22	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. BMJ: British Medical Journal, 2018, 360, j5757.	2.3	153
23	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	1.6	152
24	Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases. Breast Cancer Research and Treatment, 2007, 102, 143-155.	2.5	150
25	Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. British Journal of Cancer, 2009, 100, 487-493.	6.4	149
26	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology, 2019, 76, 831-842.	1.9	148
27	The order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes. Genes Chromosomes and Cancer, 2006, 45, 31-41.	2.8	143
28	Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Human Molecular Genetics, 2004, 13, 2303-2311.	2.9	127
29	Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis. Oncogene, 2014, 33, 2807-2813.	5.9	126
30	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	21.4	125
31	High Promoter Methylation Levels of APC Predict Poor Prognosis in Sextant Biopsies from Prostate Cancer Patients. Clinical Cancer Research, 2007, 13, 6122-6129.	7.0	122
32	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120
33	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Human Molecular Genetics, 2013, 22, 408-415.	2.9	118
34	QuantitativeRARÎ²2Hypermethylation. Clinical Cancer Research, 2004, 10, 4010-4014.	7.0	117
35	Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients. Blood, 2014, 124, 2544-2553.	1.4	102
36	Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Human Molecular Genetics, 2013, 22, 2520-2528.	2.9	100

#	Article	IF	Citations
37	TCF21andPCDH17methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics, 2011, 6, 1120-1130.	2.7	99
38	Germline Mutations in PALB2, BRCA1, and RAD51C, Which Regulate DNA Recombination Repair, in Patients With Gastric Cancer. Gastroenterology, 2017, 152, 983-986.e6.	1.3	98
39	Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas. Nature Communications, 2015, 6, 10131.	12.8	93
40	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93
41	Cytogenetic and molecular genetic analyses of endometrial stromal sarcoma: nonrandom involvement of chromosome arms 6p and 7p and confirmation of JAZF1/JJAZ1 gene fusion in t(7;17). Cancer Genetics and Cytogenetics, 2003, 144, 119-124.	1.0	92
42	ADAMTS1, CRABP1, and NR3C1 Identified as Epigenetically Deregulated Genes in Colorectal Tumorigenesis. Analytical Cellular Pathology, 2006, 28, 259-272.	1.4	92
43	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	12.8	90
44	Chromosome abnormalities in benign hyperproliferative disorders of epithelial and stromal breast tissue. International Journal of Cancer, 1995, 60, 49-53.	5.1	89
45	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	5.0	88
46	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	12.8	88
47	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	12.8	88
48	DNA repair genes are selectively mutated in diffuse large B cell lymphomas. Journal of Experimental Medicine, 2013, 210, 1729-1742.	8.5	87
49	Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. The Lancet Gastroenterology and Hepatology, 2018, 3, 489-498.	8.1	87
50	Epigenetic Heterogeneity of High-Grade Prostatic Intraepithelial Neoplasia: Clues for Clonal Progression in Prostate Carcinogenesis. Molecular Cancer Research, 2006, 4, 1-8.	3.4	85
51	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	2.4	82
52	Clonal heterogeneity in breast cancer: Karyotypic comparisons of multiple intraâ€"and extraâ€"tumorous samples from 3 patients. International Journal of Cancer, 1995, 63, 63-68.	5.1	80
53	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€"ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	12.8	78
54	The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. Cancer Causes and Control, 2015, 26, 1603-1616.	1.8	77

#	Article	IF	Citations
55	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute, 2016, 108, djv315.	6.3	77
56	Chromosome abnormalities in bilateral breast carcinomas. Cytogenetic evaluation of the clonal origin of multiple primary tumors. Cancer, 1995, 76, 250-258.	4.1	76
57	Distinct high resolution genome profiles of early onset and late onset colorectal cancer integrated with gene expression data identify candidate susceptibility loci. Molecular Cancer, 2010, 9, 100.	19.2	75
58	FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer. Genes Chromosomes and Cancer, 2012, 51, 240-249.	2.8	73
59	Blood lipids and prostate cancer: a Mendelian randomization analysis. Cancer Medicine, 2016, 5, 1125-1136.	2.8	68
60	Molecular cytogenetic characterization of proximalâ€type epithelioid sarcoma. Genes Chromosomes and Cancer, 2004, 41, 283-290.	2.8	67
61	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Human Molecular Genetics, 2015, 24, 5589-5602.	2.9	67
62	MT1G Hypermethylation Is Associated with Higher Tumor Stage in Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1274-1278.	2.5	65
63	8q Gain Is an Independent Predictor of Poor Survival in Diagnostic Needle Biopsies from Prostate Cancer Suspects. Clinical Cancer Research, 2006, 12, 3961-3970.	7.0	65
64	Genomic aberrations in carcinomas of the uterine corpus. Genes Chromosomes and Cancer, 2004, 40, 229-246.	2.8	63
65	Molecular Subtyping of Primary Prostate Cancer Reveals Specific and Shared Target Genes of Different ETS Rearrangements. Neoplasia, 2012, 14, 600-IN15.	5.3	63
66	Array CGH and gene-expression profiling reveals distinct genomic instability patterns associated with DNA repair and cell-cycle checkpoint pathways in Ewing's sarcoma. Oncogene, 2008, 27, 2084-2090.	5.9	62
67	Cytogenetic clues to breast carcinogenesis. Genes Chromosomes and Cancer, 2002, 33, 1-16.	2.8	61
68	Frequency of NUP98-NSD1 fusion transcript in childhood acute myeloid leukaemia. Leukemia, 2003, 17, 2244-2247.	7.2	61
69	Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results. Blood, 2013, 121, 2415-2423.	1.4	61
70	Frequent 14-3-3 Ïƒ Promoter Methylation in Benign and Malignant Prostate Lesions. DNA and Cell Biology, 2005, 24, 264-269.	1.9	60
71	8q24 Copy number gains and expression of the c-myc mRNA stabilizing proteinCRD-BP in primary breast carcinomas. International Journal of Cancer, 2003, 104, 54-59.	5.1	58
72	Genome signatures of colon carcinoma cell lines. Cancer Genetics and Cytogenetics, 2004, 155, 119-131.	1.0	58

#	Article	IF	Citations
73	Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer, 2007, 7, 133.	2.6	58
74	Cytogenetic analysis of multifocal breast carcinomas: detection of karyotypically unrelated clones as well as clonal similarities between tumour foci. British Journal of Cancer, 1994, 70, 922-927.	6.4	57
75	<scp>FOXE1</scp> polymorphisms are associated with familial and sporadic nonmedullary thyroid cancer susceptibility. Clinical Endocrinology, 2012, 77, 926-933.	2.4	57
76	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	5.0	57
77	Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E2572-81.	7.1	56
78	A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. Cancer Discovery, 2015, 5, 368-379.	9.4	56
79	Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. Journal of Molecular Medicine, 2006, 84, 911-918.	3.9	54
80	Genomic Changes in Chromosomes 10, 16, and X in Malignant Peripheral Nerve Sheath Tumors Identify a High-Risk Patient Group. Journal of Clinical Oncology, 2010, 28, 1573-1582.	1.6	54
81	Prediction of individual genetic risk to prostate cancer using a polygenic score. Prostate, 2015, 75, 1467-1474.	2.3	54
82	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.9	54
83	Detection of gene promoter hypermethylation in fine needle washings from breast lesions. Clinical Cancer Research, 2003, 9, 3413-7.	7.0	54
84	Cytogenetic polyclonality in tumors of the breast. Cancer Genetics and Cytogenetics, 1997, 95, 16-19.	1.0	52
85	Cytogenetic analysis shows that carcinosarcomas of the breast are of monoclonal origin. Genes Chromosomes and Cancer, 1998, 22, 145-151.	2.8	52
86	The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal. Breast Cancer Research and Treatment, 2009, 114, 31-38.	2.5	52
87	MLL-SEPTIN gene fusions in hematological malignancies. Biological Chemistry, 2011, 392, 713-724.	2.5	52
88	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	6.4	52
89	Cytogenetic comparison of primary tumors and lymph node metastases in breast cancer patients. Genes Chromosomes and Cancer, 1998, 22, 122-129.	2.8	50
90	Aberrant cellular retinol binding protein 1 (CRBP1) gene expression and promoter methylation in prostate cancer. Journal of Clinical Pathology, 2004, 57, 872-876.	2.0	50

#	Article	IF	Citations
91	Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. Human Molecular Genetics, 2015, 24, 1478-1492.	2.9	50
92	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nature Communications, 2016, 7, 10979.	12.8	50
93	Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes in early-onset/familial prostate cancer. PLoS Genetics, 2018, 14, e1007355.	3.5	50
94	Relative Copy Number Gain of MYC in Diagnostic Needle Biopsies is an Independent Prognostic Factor for Prostate Cancer Patients. European Urology, 2007, 52, 116-125.	1.9	49
95	Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	7.1	48
96	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Lancet Oncology, The, 2021, 22, 1618-1631.	10.7	48
97	Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions. Breast Cancer Research and Treatment, 2008, 109, 27-34.	2.5	47
98	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	3.5	47
99	Characterization of supernumerary rings and giant marker chromosomes in well-differentiated lipomatous tumors by a combination of G-banding, CGH, M-FISH, and chromosome- and locus-specific FISH. Cytogenetic and Genome Research, 2002, 97, 13-19.	1.1	45
100	Recurrent Fusion Oncogenes in Carcinomas. Critical Reviews in Oncogenesis, 2006, 12, 257-271.	0.4	45
101	Statistical dissection of genetic pathways involved in prostate carcinogenesis. Genes Chromosomes and Cancer, 2006, 45, 154-163.	2.8	44
102	Heterogeneous genetic profiles in soft tissue myoepitheliomas. Modern Pathology, 2008, 21, 1311-1319.	5.5	44
103	Cernunnos influences human immunoglobulin class switch recombination and may be associated with B cell lymphomagenesis. Journal of Experimental Medicine, 2012, 209, 291-305.	8.5	44
104	High resolution melting analysis of KRAS, BRAF and PIK3CA in KRASexon 2 wild-type metastatic colorectal cancer. BMC Cancer, 2013, 13, 169.	2.6	44
105	<scp>POLE</scp> somatic mutations in advanced colorectal cancer. Cancer Medicine, 2017, 6, 2966-2971.	2.8	43
106	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nature Communications, 2018, 9, 4616.	12.8	43
107	Genome characteristics of primary carcinomas, local recurrences, carcinomatoses, and liver metastases from colorectal cancer patients. Molecular Cancer, 2004, 3, 6.	19.2	42
108	SEPT2 is a new fusion partner of MLL in acute myeloid leukemia with t(2;11)(q37;q23). Oncogene, 2006, 25, 6147-6152.	5.9	42

#	Article	IF	Citations
109	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112.	5.0	42
110	Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. BMC Medicine, 2016, 14, 66.	5.5	42
111	Discrimination between multicentric and multifocal breast carcinoma by cytogenetic investigation of macroscopically distinct ipsilateral lesions. , 1997, 18, 170-174.		41
112	Feasibility of differential diagnosis of kidney tumors by comparative genomic hybridization of fine needle aspiration biopsies. Genes Chromosomes and Cancer, 2010, 49, 935-947.	2.8	41
113	Familial vs sporadic papillary thyroid carcinoma: a matched-case comparative study showing similar clinical/prognostic behaviour. European Journal of Endocrinology, 2014, 170, 321-327.	3.7	40
114	Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility. Nature Communications, 2017, 8, 1892.	12.8	40
115	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. Nature Communications, 2021, 12, 1236.	12.8	40
116	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.9	39
117	Cyclin D1 A870G polymorphism and amplification in laryngeal squamous cell carcinoma: implications of tumor localization and tobacco exposure. Cancer Detection and Prevention, 2004, 28, 237-243.	2.1	38
118	Adenomas and follicular carcinomas of the thyroid display two major patterns of chromosomal changes. Journal of Pathology, 2005, 206, 305-311.	4.5	38
119	Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications. International Journal of Molecular Sciences, 2020, 21, 5036.	4.1	38
120	Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. European Urology Oncology, 2021, 4, 570-579.	5.4	38
121	Genetic profiling of colorectal cancer liver metastases by combined comparative genomic hybridization and G-banding analysis. Genes Chromosomes and Cancer, 2003, 36, 189-197.	2.8	37
122	Detailed analysis of expression and promoter methylation status of apoptosis-related genes in prostate cancer. Apoptosis: an International Journal on Programmed Cell Death, 2010, 15, 956-965.	4.9	37
123	Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer. Cancer Genetics, 2011, 204, 439-446.	0.4	37
124	Multiple numerical chromosome aberrations in cancer: what are their causes and what are their consequences?. Seminars in Cancer Biology, 2005, 15, 3-12.	9.6	36
125	Cysteine-Rich Secretory Protein-3 (CRISP3) Is Strongly Up-Regulated in Prostate Carcinomas with the TMPRSS2-ERG Fusion Gene. PLoS ONE, 2011, 6, e22317.	2.5	36
126	Frequent copy number gains at 1q21 and 1q32 are associated with overexpression of the ETS transcription factors ETV3 and ELF3 in breast cancer irrespective of molecular subtypes. Breast Cancer Research and Treatment, 2013, 138, 37-45.	2.5	36

#	Article	IF	Citations
127	Novel 5â€² Fusion Partners of ETV1 and ETV4 in Prostate Cancer. Neoplasia, 2013, 15, 720-IN6.	5.3	36
128	Overexpression of the mitotic checkpoint genes BUB1 and BUBR1 is associated with genomic complexity in clear cell kidney carcinomas. Cellular Oncology, 2008, 30, 389-95.	1.9	36
129	Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. Scientific Reports, 2015, 5, 17369.	3.3	35
130	Conventional and molecular cytogenetics of human non-medullary thyroid carcinoma: characterization of eight cell line models and review of the literature on clinical samples. BMC Cancer, 2008, 8, 371.	2.6	34
131	Epigenetic regulation of Wnt signaling pathway in urological cancer. Epigenetics, 2010, 5, 343-351.	2.7	34
132	Fine-Mapping the HOXB Region Detects Common Variants Tagging a Rare Coding Allele: Evidence for Synthetic Association in Prostate Cancer. PLoS Genetics, 2014, 10, e1004129.	3.5	34
133	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	2.5	34
134	Identification of Two Novel HOXB13 Germline Mutations in Portuguese Prostate Cancer Patients. PLoS ONE, 2015, 10, e0132728.	2.5	34
135	Evaluation of Breast Cancer Polyclonality by Combined Chromosome Banding and Comparative Genomic Hybridization Analysis. Neoplasia, 2001, 3, 204-214.	5.3	33
136	Immunohistochemical molecular phenotypes of gastric cancer based on SOX2 and CDX2 predict patient outcome. BMC Cancer, 2014, 14, 753.	2.6	33
137	Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients. Genetics in Medicine, 2004, 6, 102-107.	2.4	32
138	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	1.3	32
139	No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin. BMC Cancer, 2005, 5, 101.	2.6	31
140	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	5.0	31
141	Chromosome banding analysis of gynecomastias and breast carcinomas in men. , 1998, 23, 16-20.		30
142	Cross-species color banding characterization of chromosomal rearrangements in leukemias with incomplete G-band karyotypes. Genes Chromosomes and Cancer, 1999, 26, 13-19.	2.8	30
143	Combined classical and molecular cytogenetic analysis of cancer. European Journal of Cancer, 2002, 38, 1580-1584.	2.8	30
144	BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families. Familial Cancer, 2006, 5, 379-387.	1.9	30

#	Article	IF	Citations
145	EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study. Tumor Biology, 2012, 33, 2061-2068.	1.8	30
146	Target gene mutational pattern in Lynch syndrome colorectal carcinomas according to tumour location and germline mutation. British Journal of Cancer, 2015, 113, 686-692.	6.4	30
147	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	6.3	30
148	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nature Communications, 2020, 11, 312.	12.8	30
149	Cytogenetic abnormalities in anin situ ductal carcinoma and five prophylactically removed breasts from members of a family with hereditary breast cancer. Breast Cancer Research and Treatment, 1996, 38, 177-182.	2.5	29
150	Common Fusion Transcripts Identified in Colorectal Cancer Cell Lines by High-Throughput RNA Sequencing. Translational Oncology, 2013, 6, 546-IN5.	3.7	29
151	Detailed Genome-Wide Screening for Inter- and Intrachromosomal Abnormalities by Sequential G-Banding and RxFISH Color Banding of the Same Metaphase Cells. Cancer Genetics and Cytogenetics, 2000, 119, 94-101.	1.0	28
152	Genomic analysis of prostate carcinoma specimens obtained via ultrasound-guided needle biopsy may be of use in preoperative decision-making. Cancer, 2004, 101, 1786-1793.	4.1	28
153	Colorectal carcinomas with microsatellite instability display a different pattern of target gene mutations according to large bowel site of origin. BMC Cancer, 2010, 10, 587.	2.6	28
154	Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. International Journal of Cancer, 2017, 140, 75-85.	5.1	28
155	Contribution of <scp>MLH</scp>1 constitutional methylation for Lynch syndrome diagnosis in patients with tumor <scp>MLH</scp>1 downregulation. Cancer Medicine, 2018, 7, 433-444.	2.8	28
156	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	5.2	28
157	An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk. Nature Communications, 2020, 11, 3905.	12.8	28
158	Altered Expression of MGMT in High-Grade Gliomas Results from the Combined Effect of Epigenetic and Genetic Aberrations. PLoS ONE, 2013, 8, e58206.	2.5	28
159	Karyotypic changes in phyllodes tumors of the breast. Cancer Genetics and Cytogenetics, 1994, 78, 200-206.	1.0	27
160	Highly sensitive detection of the MGB1 transcript (mammaglobin) in the peripheral blood of breast cancer patients. International Journal of Cancer, 2004, 108, 592-595.	5.1	27
161	International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. Breast Cancer Research and Treatment, 2011, 127, 671-679.	2.5	27
162	Genome-Wide Association Study of Prostate Cancerâ€“Specific Survival. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1796-1800.	2.5	27

#	Article	IF	Citations
163	A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1731-1738.	2.5	27
164	Karyotypic Evolution in Breast Carcinomas with i(1)(q10) and der(1;16)(q10;p10) as the Primary Chromosome Abnormality. Cancer Genetics and Cytogenetics, 1999, 113, 156-161.	1.0	26
165	Cytogenetic characterization of tumors of the vulva and vagina. Genes Chromosomes and Cancer, 2003, 38, 137-148.	2.8	26
166	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	5.0	26
167	Assessing the role of insulinâ€like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels. International Journal of Cancer, 2016, 139, 1520-1533.	5.1	26
168	The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer. Familial Cancer, 2016, 15, 111-121.	1.9	26
169	Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer. BMC Genomics, 2017, 18, 270.	2.8	26
170	Combined RxFISH/G-banding allows refined karyotyping of solid tumors. Human Genetics, 1999, 104, 370-375.	3.8	25
171	A universal assay for detection of oncogenic fusion transcripts by oligo microarray analysis. Molecular Cancer, 2009, 8, 5.	19.2	25
172	Li-Fraumeni-like syndrome associated with a large BRCA1 intragenic deletion. BMC Cancer, 2012, 12, 237.	2.6	25
173	Carcinoma of the Thyroid With Ewing Family Tumor Elements and Favorable Prognosis. International Journal of Surgical Pathology, 2014, 22, 260-265.	0.8	25
174	Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancerâ€"an European consensus statement and expert recommendations. European Journal of Cancer, 2019, 106, 54-60.	2.8	25
175	Relative 8q gain predicts diseaseâ€specific survival irrespective of the TMPRSS2â€ERG fusion status in diagnostic biopsies of prostate cancer. Genes Chromosomes and Cancer, 2011, 50, 662-671.	2.8	24
176	Genomic characterization of two large Alu-mediated rearrangements of the BRCA1 gene. Journal of Human Genetics, 2013, 58, 78-83.	2.3	24
177	Pathogenicity Evaluation of BRCA1 and BRCA2 Unclassified Variants Identified in Portuguese Breast/Ovarian Cancer Families. Journal of Molecular Diagnostics, 2014, 16, 324-334.	2.8	24
178	Recurrent Coding Sequence Variation Explains Only A Small Fraction of the Genetic Architecture of Colorectal Cancer. Scientific Reports, 2015, 5, 16286.	3.3	24
179	The role of targeted <scp>BRCA1</scp>/<scp>BRCA2</scp> mutation analysis in hereditary breast/ovarian cancer families of Portuguese ancestry. Clinical Genetics, 2015, 88, 41-48.	2.0	24
180	Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovarian cancer. Oncotarget, 2018, 9, 17334-17348.	1.8	24

#	Article	IF	Citations
181	Specific and redundant activities ofETV1andETV4in prostate cancer aggressiveness revealed by co-overexpression cellular contexts. Oncotarget, 2015, 6, 5217-5236.	1.8	24
182	Complete cytogenetic characterization of the human breast cancer cell line MA11 combining G-banding, comparative genomic hybridization, multicolor fluorescence in situ hybridization, RxFISH, and chromosome-specific painting. Cancer Genetics and Cytogenetics, 2001, 131, 25-30.	1.0	23
183	CSF1R copy number changes, point mutations, and RNA and protein overexpression in renal cell carcinomas. Modern Pathology, 2009, 22, 744-752.	5.5	23
184	Epigenetic regulation of <scp>EFEMP</scp>1 in prostate cancer: biological relevance and clinical potential. Journal of Cellular and Molecular Medicine, 2014, 18, 2287-2297.	3.6	23
185	Pathologic Findings in Prophylactic and Nonprophylactic Hysterectomy Specimens of Patients With Lynch Syndrome. American Journal of Surgical Pathology, 2016, 40, 1177-1191.	3.7	23
186	Polyunsaturated fatty acids and prostate cancer risk: a Mendelian randomisation analysis from the PRACTICAL consortium. British Journal of Cancer, 2016, 115, 624-631.	6.4	23
187	Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity. Breast Cancer Research and Treatment, 2016, 159, 245-256.	2.5	23
188	Identification of somatic <scp>TERT</scp> promoter mutations in familial nonmedullary thyroid carcinomas. Clinical Endocrinology, 2017, 87, 394-399.	2.4	23
189	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	2.8	23
190	Karyotypic Findings in Tumors of the Vulva and Vagina. Cancer Genetics and Cytogenetics, 1999, 111, 87-91.	1.0	22
191	Chromosome analysis and molecular cytogenetic investigations of an epithelioid hemangioendothelioma. Cancer Genetics and Cytogenetics, 2006, 169, 164-168.	1.0	22
192	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	2.5	22
193	BRCA1 and BRCA2 rearrangements in Brazilian individuals with Hereditary Breast and Ovarian Cancer Syndrome. Genetics and Molecular Biology, 2016, 39, 223-231.	1.3	22
194	MSH6 germline mutations in early-onset colorectal cancer patients without family history of the disease. British Journal of Cancer, 2006, 95, 752-756.	6.4	21
195	Cytogenetic Analysis of Tumor Clonality. Advances in Cancer Research, 2011, 112, 127-149.	5.0	21
196	A novel exonic rearrangement affecting MLH1 and the contiguous LRRFIP2 is a founder mutation in Portuguese Lynch syndrome families. Genetics in Medicine, 2011, 13, 895-902.	2.4	21
197	Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 208-216.	2.5	21
198	Potential Downstream Target Genes of Aberrant ETS Transcription Factors Are Differentially Affected in Ewingâ€™s Sarcoma and Prostate Carcinoma. PLoS ONE, 2012, 7, e49819.	2.5	21

#	Article	IF	Citations
199	Chromosome Mechanisms Giving Rise to the TMPRSS2-ERG Fusion Oncogene in Prostate Cancer and HGPIN Lesions. American Journal of Surgical Pathology, 2008, 32, 640-644.	3.7	20
200	Mitochondrial genome alterations in rectal and sigmoid carcinomas. Cancer Letters, 2009, 280, 38-43.	7.2	20
201	Potential clinical applications of circulating cell-free DNA in ovarian cancer patients. Expert Reviews in Molecular Medicine, 2018, 20, e6.	3.9	20
202	Acute Myeloid Leukemia with inv(8)(p11q13). Leukemia and Lymphoma, 2000, 39, 651-656.	1.3	19
203	Comparison of chromosomal and array-based comparative genomic hybridization for the detection of genomic imbalances in primary prostate carcinomas. Molecular Cancer, 2006, 5, 33.	19.2	19
204	Expression pattern of the septin gene family in acute myeloid leukemias with and without MLL-SEPT fusion genes. Leukemia Research, 2010, 34, 615-621.	0.8	19
205	Genetic and clinical characterization of 45 acute leukemia patients with MLL gene rearrangements from a single institution. Molecular Oncology, 2012, 6, 553-564.	4.6	19
206	Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 472 for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group. JCO Precision Oncology, 2018, 2, 1-42.	3.0	19
207	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	6.4	19
208	Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	6.3	19
209	Cytogenetic analysis of several pseudomyxoma peritonei lesions originating from a mucinous cystadenoma of the appendix. Cancer Genetics and Cytogenetics, 1997, 93, 157-159.	1.0	18
210	Carcinoma of the Thyroid With Ewing/PNET Family Tumor Elements. International Journal of Surgical Pathology, 2014, 22, 579-581.	0.8	18
211	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	1.4	18
212	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	2.5	18
213	Expression changes of the MAD mitotic checkpoint gene family in renal cell carcinomas characterized by numerical chromosome changes. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 450, 379-385.	2.8	17
214	Molecular characterization of the MLL-SEPT6 fusion gene in acute myeloid leukemia: identification of novel fusion transcripts and cloning of genomic breakpoint junctions. Haematologica, 2008, 93, 1076-1080.	3.5	17
215	Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients. BMC Cancer, 2010, 10, 470.	2.6	17
216	Hereditary gastrointestinal stromal tumors sharing the KIT Exon 17 germline mutation p.Asp820Tyr develop through different cytogenetic progression pathways. Genes Chromosomes and Cancer, 2010, 49, 91-98.	2.8	17

#	Article	IF	Citations
217	Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. British Journal of Cancer, 2016, 114, 945-952.	6.4	17
218	Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis. International Journal of Cancer, 2017, 140, 322-328.	5.1	17
219	Genome profiling of breast cancer cells selected against in vitro shows copy number changes. Genes Chromosomes and Cancer, 2002, 33, 304-309.	2.8	16
220	Acute megakaryoblastic leukemia with a fourâ€way variant translocation originating the RBM15â€“MKL1 fusion gene. Pediatric Blood and Cancer, 2011, 56, 846-849.	1.5	16
221	12q amplification defines a subtype of extraskeletal osteosarcoma with good prognosis that is the soft tissue homologue of parosteal osteosarcoma. Cancer Genetics, 2012, 205, 332-336.	0.4	16
222	Deregulation of <scp>PAX</scp>2 expression in renal cell tumours: mechanisms and potential use in differential diagnosis. Journal of Cellular and Molecular Medicine, 2013, 17, 1048-1058.	3.6	16
223	The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. Cancers, 2020, 12, 3254.	3.7	16
224	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 532-541.	3.9	16
225	The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	2.4	16
226	Chromosome copy number changes carry prognostic information independent of KIT/PDGFRA point mutations in gastrointestinal stromal tumors. BMC Medicine, 2010, 8, 26.	5.5	15
227	Transcriptome instability as a molecular pan-cancer characteristic of carcinomas. BMC Genomics, 2014, 15, 672.	2.8	15
228	Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas. PLoS ONE, 2016, 11, e0161438.	2.5	15
229	Truncating and missense PPM1D mutations in earlyâ€onset and/or familial/hereditary prostate cancer patients. Genes Chromosomes and Cancer, 2016, 55, 954-961.	2.8	15
230	Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution. BMC Cancer, 2018, 18, 1245.	2.6	15
231	TP53 germline mutations in Portugal and genetic modifiers of age at cancer onset. Familial Cancer, 2009, 8, 383-390.	1.9	14
232	Intraepidermal epidermotropic metastatic melanoma: a clinical and histopathological mimicker of melanoma in situ occurring in multiplicity. Journal of Cutaneous Pathology, 2011, 38, 514-520.	1.3	14
233	Desmoplastic Small Round Cell Tumor: Diagnosis by Fine-Needle Aspiration Cytology. Acta Cytologica, 2012, 56, 576-580.	1.3	14
234	BMP2 / BMP4 colorectal cancer susceptibility loci in northern and southern European populations. Carcinogenesis, 2013, 34, 314-318.	2.8	14

#	Article	IF	Citations
235	NCOA2 is a candidate target gene of 8q gain associated with clinically aggressive prostate cancer. Genes Chromosomes and Cancer, 2016, 55, 365-374.	2.8	14
236	The effect of sample size on polygenic hazard models for prostate cancer. European Journal of Human Genetics, 2020, 28, 1467-1475.	2.8	14
237	Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Prostate Cancer and Prostatic Diseases, 2022, 25, 755-761.	3.9	14
238	Multimodal genetic diagnosis of solid variant alveolar rhabdomyosarcoma. Cancer Genetics and Cytogenetics, 2005, 163, 138-143.	1.0	13
239	Cryptic chromosome rearrangement resulting in SYT-SSX2 fusion gene in a monophasic synovial sarcoma. Cancer Genetics and Cytogenetics, 2008, 187, 45-49.	1.0	13
240	Coexistence of alternative MLLâ€“SEPT9 fusion transcripts in an acute myeloid leukemia with t(11;17)(q23;q25). Cancer Genetics and Cytogenetics, 2010, 197, 60-64.	1.0	13
241	The <scp>MSH2</scp> c.388_389del mutation shows a founder effect in Portuguese Lynch syndrome families. Clinical Genetics, 2013, 84, 244-250.	2.0	13
242	Validation of a Next-Generation Sequencing Pipeline for the Molecular Diagnosis of Multiple Inherited Cancer Predisposing Syndromes. Journal of Molecular Diagnostics, 2017, 19, 502-513.	2.8	13
243	High frequency of clonal chromosome abnormalities in prostatic neoplasms sampled by prostatectomy or ultrasound-guided needle biopsy. , 2000, 28, 211-219.		12
244	POU1F1 is a novel fusion partner of NUP98 in acute myeloid leukemia with t(3;11)(p11;p15). Molecular Cancer, 2013, 12, 5.	19.2	12
245	Prostate Cancer Prognosis Defined by the Combined Analysis of 8q, PTEN and ERG. Translational Oncology, 2016, 9, 575-582.	3.7	12
246	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. British Journal of Cancer, 2018, 118, 266-276.	6.4	12
247	Detection of microsatellite instability (MSI) in colorectal cancer samples with a novel set of highly sensitive markers by means of the Idylla MSI Test prototype.. Journal of Clinical Oncology, 2018, 36, e15639-e15639.	1.6	12
248	Carcinogenic ability of possibly through oncogenic mutation of gene. Advances in Cancer: Research & Treatment, 2013, 2013, .	0.0	12
249	Both SEPT2 and MLL are down-regulated in MLL-SEPT2therapy-related myeloid neoplasia. BMC Cancer, 2009, 9, 147.	2.6	11
250	Haplotype and quantitative transcript analyses of Portuguese breast/ovarian cancer families with the BRCA1 R71G founder mutation of Galician origin. Familial Cancer, 2009, 8, 203-208.	1.9	11
251	Identification of previously unrecognized FAP in children with Gardner fibroma. European Journal of Human Genetics, 2015, 23, 715-718.	2.8	11
252	Oncogenic mechanisms of HOXB13 missense mutations in prostate carcinogenesis. Oncoscience, 2016, 3, 288-296.	2.2	11

#	Article	IF	Citations
253	SNP interaction pattern identifier (SIPI): an intensive search for SNPâ€“SNP interaction patterns. Bioinformatics, 2017, 33, 822-833.	4.1	11
254	Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report. BMC Cancer, 2018, 18, 1229.	2.6	11
255	Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects. Frontiers in Oncology, 2020, 10, 1318.	2.8	11
256	The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases. Cancers, 2020, 12, 292.	3.7	11
257	Uncovering potential downstream targets of oncogenic GRPR overexpression in prostate carcinomas harboring ETS rearrangements. Oncoscience, 2015, 2, 497-507.	2.2	11
258	Portuguese c.156_157insAlu BRCA2 founder mutation: gastrointestinal and tongue neoplasias may be part of the phenotype. Familial Cancer, 2012, 11, 657-660.	1.9	10
259	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	2.5	10
260	Surveillance of succinate dehydrogenase gene mutation carriers: Insights from a nationwide cohort. Clinical Endocrinology, 2020, 92, 545-553.	2.4	10
261	A novel spliced fusion of MLL with CT45A2in a pediatric biphenotypic acute leukemia. BMC Cancer, 2010, 10, 518.	2.6	9
262	PNET with neuroendocrine differentiation of the lung. International Journal of Surgical Pathology, 2014, 22, 427-433.	0.8	9
263	Re: Role of the Oxidative DNA Damage Repair Gene OGG1 in Colorectal Tumorigenesis. Journal of the National Cancer Institute, 2014, 106, .	6.3	9
264	Ovarian metastasis from uveal melanoma with MLH1/PMS2 protein loss in a patient with germline MLH1 mutated Lynch syndrome: consequence or coincidence?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 347-352.	2.8	9
265	Haplotype analysis of the internationally distributed BRCA1 c.3331_3334delCAAG founder mutation reveals a common ancestral origin in Iberia. Breast Cancer Research, 2020, 22, 108.	5.0	9
266	Identification of SPRY4 as a Novel Candidate Susceptibility Gene for Familial Nonmedullary Thyroid Cancer. Thyroid, 2021, 31, 1366-1375.	4.5	9
267	Telomerase Activity and Genetic Alterations in Primary Breast Carcinomas. Neoplasia, 2003, 5, 170-178.	5.3	8
268	The loss of NKX3.1 expression in testicular--and prostate--cancers is not caused by promoter hypermethylation. Molecular Cancer, 2005, 4, 8.	19.2	8
269	Genetic diagnosis of alveolar rhabdomyosarcoma in the bone marrow of a patient without evidence of primary tumor. Pediatric Blood and Cancer, 2008, 51, 554-557.	1.5	8
270	Molecular diagnosis of the Portuguese founder mutation BRCA2 c.156_157insAlu. Breast Cancer Research and Treatment, 2009, 117, 215-217.	2.5	8

#	Article	IF	Citations
271	Altered expression of key cell cycle regulators in renal cell carcinoma associated with Xp11.2 translocation. Pathology Research and Practice, 2009, 205, 466-472.	2.3	8
272	Variability of the paracrineâ€induced osteoclastogenesis by human breast cancer cell lines. Journal of Cellular Biochemistry, 2012, 113, 1069-1079.	2.6	8
273	Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somaticTMPRSS2:ERGfusion status. Human Molecular Genetics, 2016, 25, ddw349.	2.9	8
274	Co-occurrence of nonsense mutations in MSH6 and MSH2 in Lynch syndrome families evidencing that not all truncating mutations are equal. Journal of Human Genetics, 2016, 61, 151-156.	2.3	8
275	TP53mutations are associated with a particular pattern of genomic imbalances in breast carcinomas. Journal of Pathology, 2005, 207, 14-19.	4.5	7
276	Correspondence: SEMA4A variation and risk of colorectal cancer. Nature Communications, 2016, 7, 10611.	12.8	7
277	Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. British Journal of Cancer, 2017, 117, 734-743.	6.4	7
278	Fluorescence in situ hybridization of old G-banded and mounted chromosome preparations. Cancer Genetics and Cytogenetics, 1997, 98, 9-15.	1.0	6
279	The Brazilian Founder MutationTP53p.R337H is Uncommon in Portuguese Women Diagnosed with Breast Cancer. Breast Journal, 2014, 20, 534-536.	1.0	6
280	Screening and characterization of BRCA2 c.156_157insAlu in Brazil: Results from 1380 individuals from the South and Southeast. Cancer Genetics, 2018, 228-229, 93-97.	0.4	6
281	Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond BRCA1/BRCA2. Cancers, 2020, 12, 2834.	3.7	6
282	Karyotypic divergence and convergence in two synchronous lung metastases of a clear cell sarcoma of tendons and aponeuroses with t(12;22)(q13;q12) and type 1 EWS/ATF1. Cancer Genetics and Cytogenetics, 2003, 145, 121-125.	1.0	5
283	Multicentric mammary carcinoma. Cancer, 2003, 97, 715-717.	4.1	5
284	Genotypic and phenotypic classification of cancer: How should the impact of the two diagnostic approaches best be balanced?. Genes Chromosomes and Cancer, 2010, 49, 763-774.	2.8	5
285	Endometrial endometrioid adenocarcinoma associated with primitive neuroectodermal tumour of the uterus: a poor prognostic subtype of uterine tumours. Medical Oncology, 2011, 28, 1488-1494.	2.5	5
286	Widening the spectrum of Lynch syndrome: first report of testicular seminoma attributable to MSH2 loss. Histopathology, 2020, 76, 486-489.	2.9	5
287	Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. Npj Breast Cancer, 2020, 6, 44.	5.2	5
288	KLK3 SNPâ€“SNP interactions for prediction of prostate cancer aggressiveness. Scientific Reports, 2021, 11, 9264.	3.3	5

#	Article	IF	Citations
289	Next Generation Sequencing of Tumor and Matched Plasma Samples: Identification of Somatic Variants in ctDNA From Ovarian Cancer Patients. Frontiers in Oncology, 2021, 11, 754094.	2.8	5
290	A novel MLL-SEPT2 fusion variant in therapy-related myelodysplastic syndrome. Cancer Genetics and Cytogenetics, 2008, 185, 62-64.	1.0	4
291	Case Report: Pheochromocytoma and Synchronous Neuroblastoma in a Family With Hereditary Pheochromocytoma Associated With a MAX Deleterious Variant. Frontiers in Endocrinology, 2021, 12, 609263.	3.5	4
292	Hybrid oncocytic/chromophobe renal cell tumor: An integrated genetic and epigenetic characterization of a case. Experimental and Molecular Pathology, 2018, 105, 352-356.	2.1	3
293	AA9int: SNP interaction pattern search using non-hierarchical additive model set. Bioinformatics, 2018, 34, 4141-4150.	4.1	3
294	The nonsense mutation MSH2 c.2152C>T shows a founder effect in Portuguese Lynch syndrome families. Genes Chromosomes and Cancer, 2019, 58, 657-664.	2.8	3
295	Assessment of Fusion Gene Status in Sarcomas Using a Custom Made Fusion Gene Microarray. PLoS ONE, 2013, 8, e70649.	2.5	3
296	Expression Profiling in Ovarian Cancer Reveals Coordinated Regulation of BRCA1/2 and Homologous Recombination Genes. Biomedicines, 2022, 10, 199.	3.2	3
297	KRAS and NRAS mutational analysis in plasma ctDNA from patients with metastatic colorectal cancer by real-time PCR and digital PCR. International Journal of Colorectal Disease, 2022, 37, 895-905.	2.2	3
298	Translocation (3;3)(p14;q29) as the Primary Chromosome Abnormality in a Peritoneal Mesothelioma. Cancer Genetics and Cytogenetics, 1998, 103, 73-75.	1.0	2
299	Molecular characterization of a rare MLLâ€“AF4 (MLLâ€“AFF1) fusion rearrangement in infant leukemia. Cancer Genetics and Cytogenetics, 2007, 178, 61-64.	1.0	2
300	Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Human Molecular Genetics, 2013, 22, 4239-4239.	2.9	2
301	Lapatinib-capecitabine versus capecitabine alone as radiosensitizers in RAS wild-type resectable rectal cancer, an adaptive randomized phase II trial (LaRRC trial): study protocol for a randomized controlled trial. Trials, 2016, 17, 459.	1.6	2
302	Performance of Lynch syndrome predictive models in quantifying the likelihood of germline mutations in patients with abnormal MLH1 immunoexpression. Familial Cancer, 2017, 16, 73-81.	1.9	2
303	The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer. Familial Cancer, 2021, 20, 173-180.	1.9	2
304	Multi-Gene Panel Testing in Gastroenterology: Are We Ready for the Results?. GE Portuguese Journal of Gastroenterology, 2021, 28, 1-7.	0.8	2
305	Molecular classification of endometrial carcinoma: protocol for a cohort study (Preprint). JMIR Research Protocols, 0, , .	1.0	2
306	Negative MR4Â·0chronic myeloid leukaemia and its possible implications for treatmentâ€free remission. British Journal of Haematology, 2019, 186, e181-e184.	2.5	1

#	Article	IF	Citations
307	When to Stop TKIs in Patients with Chronic Myeloid Leukemia and How to Follow Them Subsequently. Current Treatment Options in Oncology, 2021, 22, 49.	3.0	1
308	Myeloid Disease with the CSF3R T618I Mutation after CLL. Case Reports in Hematology, 2020, 2020, 1-4.	0.4	1
309	Male gender as a poor prognostic factor in Medullary Thyroid Carcinoma: behaviour or biological difference?. Minerva Endocrinology, 2022, , .	1.1	1
310	Cytogenetic Approaches to Breast Cancer. , 1999, , 373-388.		0
311	Reply to AnnaMaria Cianciulli, Roberta Merola and Costantino Leonardoâ€™s Letter to the Editor re: Franclim R. Ribeiro, Rui Henrique, Ana T. Martins, Carmen JerÃ³nimo and Manuel R. Teixeira. Relative Copy Number Gain of MYC in Diagnostic Needle Biopsies is an Independent Prognostic Factor for Prostate Cancer Patients. Eur Urol 2007;52:116â€“25. European Urology, 2007, 52, 1539-1540.	1.9	0
312	After Angelina and the Supreme Court Decision, where do we go from here? BRCA gene testing in Rhode Island's Portuguese population. American Journal of Medical Genetics, Part A, 2014, 164, 557-558.	1.2	0
313	Pathogenicity reclassification of two BRCA1/BRCA2 exonic duplications after identification of genomic breakpoints and tandem orientation. Cancer Genetics, 2020, 248-249, 18-24.	0.4	0
314	Prognostic Impact of High Hematogones in Acute Myeloid Leukemia. Blood, 2012, 120, 1435-1435.	1.4	0
315	Abstract 1281: Identification of novel susceptibility genes in familial gastric cancer using next generation sequencing and identity-by-descent mapping. , 2014, , .		0
316	Abstract 2739: Transcontinental characterization of the Hispanic BRCA1 3450del4 breast cancer founder mutation. , 2015, , .		0
317	Abstract LB-158: Germline mutations inPALB2,BRCA1andRAD51Cobserved in gastric cancer cases. , 2017, , .		0
318	Array-Based Comparative Genomic Hybridization in Prostate Cancer: Research and Clinical Applications. , 2008, , 415-429.		0
319	Prognostic Value of Histone Modifying Enzyme EZH2 in RCHOP-Treated Diffuse Large B-Cell Lymphoma and High Grade B-Cell Lymphoma. Journal of Personalized Medicine, 2021, 11, 1384.	2.5	0